Department of Cardiovascular Diseases, Mayo Clinic, Rochester, MN.
Division of Cardiology, West Virginia University School of Medicine, Morgantown.
Mayo Clin Proc. 2019 May;94(5):864-874. doi: 10.1016/j.mayocp.2018.09.025. Epub 2019 Apr 5.
Oral anticoagulation is the dominant strategy for stroke prevention in patients with nonvalvular atrial fibrillation. However, lifelong oral anticoagulation is associated with major issues including inappropriate dosing, nonadherence, and adverse effects. Therefore, efforts have been made to develop site-specific therapy aimed to occlude the left atrial appendage, the anatomical site accountable for more than 90% of nonvalvular atrial fibrillation-related ischemic strokes. This review focuses on the growing literature to put into perspective the risk-balance ratio of left atrial appendage occlusion.
口服抗凝是预防非瓣膜性心房颤动患者中风的主要策略。然而，终身口服抗凝治疗存在一些重大问题，包括剂量不当、不遵医嘱和不良反应。因此，人们一直在努力开发针对特定部位的治疗方法，旨在闭塞左心耳，该解剖部位是导致超过 90%非瓣膜性心房颤动相关缺血性中风的原因。本综述重点关注日益增多的文献，以了解左心耳闭塞的风险平衡比。
